Human Metabolome Technologies, Inc. is a Japan-based biotechnology company developing capillary electrophoresis mass spectrometry (CE-MS)-based metabolomics technologies with two core business pillars, metabolome analysis service and biomarker discovery. HMT has one of the world’s most advanced metabolome analysis technology and has developed an original software analysis platform along with measuring technologies, such as CE-MS, LC-MS and MS/MS.
HMT provides support for customers’ R&D needs in various fields such as pharmaceuticals, medicine, food, and chemistry. Furthermore, we are also engaged in the research and development of biomarkers related to mental illness and lifestyle diseases, and we strive to contribute towards preventive and personalized medicine in the near future.
The CE-MS method was developed in 2002 by Professor Tomoyoshi Soga of the Institute for Advanced Biosciences (IAB), Keio University, one of HMT’s co-founders, as an analytical technique to simultaneously measure metabolites (metabolome), which are known to exist in tens of thousands of types in cells, in a short period of time. One of the other co-founders of HMT, Professor Masaru Tomita, Director of IAB, is recognized leader in computational biology and metabolomics who has carried out research on computer simulations of cellular metabolism for over 20 years.
HMT’s CE-MS has since garnered attention as an analytical method that overcomes the shortcomings of conventional methods, such as the inability to analyze only specific metabolites and the complexity of analytical processing.
In addition to providing high performance metabolomics, HMT is actively involved in the advancement and popularization of metabolomics through technical collaboration with IAB, and the development of the CE-MS method under a joint research agreement with Agilent Technologies, Inc.
Please feel free to contact us if you are interested in our metabolome analysis technology.